At present, four P2X3 and P2X2/3R allosteric antagonists are under evaluation in different phases of clinical trials for the treatment of patients suffering of overactive bladder, diabetic neuropathies, endometriosis, and refractory chronic cough. Here, P2RX2 is linked to overactive bladder.